GSK Updates Market on Total Voting Rights and Share Capital

GlaxoSmithKline ( (GB:GSK) ) has shared an update.

GSK has announced that its issued share capital as of 30 April 2026 stands at 4,316,202,660 ordinary shares, of which 261,378,286 are held in treasury and do not carry voting rights. This leaves a total of 4,054,824,374 voting rights, a key reference figure for investors assessing whether they must disclose holdings or changes in their positions under UK financial transparency rules.

The updated voting rights figure helps ensure compliance with the Financial Conduct Authority’s disclosure and transparency regime, providing clarity to shareholders and the market on the company’s capital structure. While the announcement is largely administrative, it underpins orderly market conduct and supports accurate regulatory reporting for institutional and retail investors holding GSK shares.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £1940.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GSK Stock

According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.

The score is driven by solid underlying financial performance and attractive valuation (moderate P/E and healthy dividend). These positives are tempered by weak technical momentum (below major moving averages with negative MACD) and earnings-call-flagged risks like FX headwinds and launch/execution ramp timing, despite constructive 2026 guidance.

To see Spark’s full report on GSK stock, click here.

More about GlaxoSmithKline

GSK is a global biopharmaceutical company that focuses on uniting science, technology and talent to develop medicines and vaccines aimed at getting ahead of disease. Headquartered in London and registered in England and Wales, it operates internationally with a core mission centered on improving health outcomes for patients worldwide.

Average Trading Volume: 9,614,662

Technical Sentiment Signal: Buy

Current Market Cap: £76.99B

See more insights into GSK stock on TipRanks’ Stock Analysis page.